Hermann Nabi, PhD, HDR, is a regular researcher in the Oncology division at CHU de Québec-Université Laval Research Center and Assistant Professor of Epidemiology at the Department of Social and Preventive Medicine at the Faculty of Medicine of Université Laval. Prior to joining the Center and Université Laval in 2016, Dr. Nabi headed the Research Department of Social and Human Sciences, Epidemiology, Public Health at the Institut National du Cancer(INCa) and was a regular researcher at l’Institut National de la Santé et de la Recherche Médicale(INSERM U.1018) in France.

His team’s work focuses on precision medicine, this emerging medical approach for disease prevention and treatment that takes into account individual differences in genes, environment and lifestyle for each person. With advances in genomics and the advent of new molecular biology technologies, precision medicine is attracting a lot of attention and has become an area of ​​strong international competition. However, despite the large volume and unprecedented rate of gene or biomarker discoveries, relatively few have reached the bedside or contributed to improving the health of populations. This relative poor performance could be explained by the fact that only a small proportion (about 3%) of all published global research addresses issues related to the integration of genomics innovations into health and disease prevention. For this reason, the ultimate goal of Dr. Nabi’s team is to generate evidence to facilitate a successful and responsible integration of precision medicine innovations into health care and prevention, particularly for cancer.

To achieve this goal, his work is organized around three main objectives:

1) Characterize the mechanisms and organizational implications of the progressive adoption of innovations in precision medicine in oncology,

2) Evaluate the impact of diagnostic and therapeutic innovations in precision medicine on the quality of life and clinical outcomes of cancer patients and the effectiveness for the health system,

3) Develop and evaluate intervention methods to support the integration of innovations, which takes into account patients and populations’ preferences, economic, accessibility and impact issues, in a knowledge transfer perspective.

The originality of this research program lies in its interdisciplinary approach, which combines a variety of skills and methodological tools to answer questions that are at the interface of several scientific fields. This approach proposes a new way of approaching translational research (the transfer of discoveries from laboratory to bedside), through the use of concepts, models and methods  the human and social sciences, epidemiology, public health, health services research and implementation science.

Hôpital Saint-Sacrement
1050, Chemin Ste-Foy
J0-01
Québec, Qc
Canada G1S 4L8
100 entries « 1 of 10 »

Lapointe J, Buron AC, Mbuya-Bienge C, Dorval M, Pashayan N, Brooks JD, Walker MJ, Chiquette J, Eloy L, Blackmore K, Turgeon A, Lambert-Côté L, Leclerc L, Dalpé G, Joly Y, Knoppers BM, Chiarelli AM, Simard J, Nabi H

Polygenic risk scores and risk-stratified breast cancer screening: Familiarity and perspectives of health care professionals

Journal Article

Genet Med, 2022.

Abstract | Links:

Charron M, Kaiser B, Dauge A, Gallois H, Lapointe J, Dorval M, Nabi H, Joly Y

Integrating hereditary breast and ovarian cancer genetic counselling and testing into mainstream clinical practice: Legal and ethical challenges

Journal Article

Crit Rev Oncol Hematol, 178 , 2022.

Abstract | Links:

Nabi H

Personalized Approaches for the Prevention and Treatment of Breast Cancer

Journal Article

J Pers Med, 12 (8), 2022.

Abstract | Links:

Hébert J, Bergeron AS, Veillette AM, Bouchard K, Nabi H, Dorval M

Issues associated with a hereditary risk of cancer: Knowledge, attitudes and practices of nurses in oncology settings

Journal Article

Can Oncol Nurs J, 32 (2), 2022.

Abstract | Links:

Hébert J, Bergeron AS, Veillette AM, Bouchard K, Nabi H, Dorval M

Enjeux associés au risque héréditaire de cancer: connaissances, attitudes et pratiques infirmières en oncologie

Journal Article

Can Oncol Nurs J, 32 (2), 2022.

| Links:

Cléophat JE, Dorval M, El Haffaf Z, Chiquette J, Collins S, Malo B, Fradet V, Joly Y, Nabi H

Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findings

Journal Article

BMC Med Genomics, 14 (1), 2021.

Abstract | Links:

Villafane-Bernier C, Lapointe J, Raîche C, Lauzier S, Chiquette J, Bouchard K, Pelletier S, Omeranovic A, Rhéaume J, Brousseau C, Hébert J, Dorval M, Nabi H

Cross-Cultural Adaptation and Validation of a French Version of the Genetic Counseling Satisfaction Scale (GCSS) as an Outcome Measure of Genetic Counseling for Hereditary Breast and Ovarian Cancer

Journal Article

Healthcare (Basel), 9 (9), 2021.

Abstract | Links:

Gagnet S, Diorio C, Provencher L, Mbuya-Bienge C, Lapointe J, Morin C, Lemieux J, Nabi H

Identifying Clinicopathological Factors Associated with Oncotype DX 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Pashayan N, Antoniou AC, Lee A, Wolfson M, Chiquette J, Eloy L, Eisen A, Stockley TL, Nabi H, Brooks JD, Dorval M, Easton DF, Knoppers BM, Chiarelli AM, Simard J

Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Brooks JD, Nabi HH, Andrulis IL, Antoniou AC, Chiquette J, Després P, Devilee P, Dorval M, Droit A, Easton DF, Eisen A, Eloy L, Fienberg S, Goldgar D, Hahnen E, Joly Y, Knoppers BM, Lofters A, Masson JY, Mittmann N, Paquette JS, Pashayan N, Schmutzler R, Stockley T, Tavtigian SV, Walker MJ, Wolfson M, Chiarelli AM, Simard J

Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I)

Journal Article

J Pers Med, 11 (6), 2021.

Abstract | Links:

100 entries « 1 of 10 »
Signaler des ajouts ou des modifications

Active projects

  • Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II), from 2017-11-01 to 2024-03-31
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2023-03-01
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2023-01-14

Recently finished projects

  • Conseil génétique concernant le risque héréditaire de cancer du sein: Comment améliorer l’offre de services pour préserver la qualité de vie et la satisfaction des femmes potentiellement à risque?, from 2019-01-01 to 2021-01-31
  • Enjeux de l’intégration de la Médecine de Précision en Oncologie : mieux comprendre pour mieux agir (teMPO), from 2018-07-01 to 2022-06-30
  • Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente, from 2020-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery